• Latest – submit your abstract now


Professor Vincenzo Bronte

University of Verona


Prof. Vincenzo Bronte, M.D., started his research career at University of Padova (Italy) then moved to the Surgery Branch of National Institutes of Health (NIH, Bethesda, USA) in Dr. Restifo’s laboratory, where he was actively involved in cancer immunology and immunotherapy researches. During these years, Prof. Bronte was among the pioneers to define and characterize myeloid cells with immunoregulatory functions that are now called myeloid-derived suppressor cells (MDSCs) and whose activity can restrain the efficacy of novel immunotherapeutic drugs. After that experience abroad, Prof. Bronte returned to Italy at the University of Padova/Azienda Ospedaliera and Verona University. Prof. Bronte contributed to the characterization of the molecular and enzymatic pathways that control and drive the MDSC-dependent immunosuppressive activity. He discovered, for the first time, MDSCs in tumor-bearing mice and the immune regulatory role for the metabolism of the amino acid arginine by the enzymes nitric oxide synthase and arginase. He participated in exploiting MDSC as a potential biomarker of cancer patient clinical stage and response to therapy, as well as defining molecular targets to alter their negative effects in tumor-bearing hosts, a concept that is now tested in several clinical trials. Prof. Bronte showed that arginase and nitric oxide synthase enzymes activities in human prostate-cancer cells can restrain the activation of tumor-infiltrating T cells. This study was among the first to define the possibility of modifying “cold” tumor-microenvironment using chemical compounds able to restore T cell fitness.

He is author of 181 articles published in peer-reviewed journals. His H-index is 68 (i10-index of 129) with an amount of about 24,908 citations by Google Scholar database. He was included in the list of Highly Cited Researchers for 2018 by Clarivate Analytics (147 scientists in total in the Immunology field). This list recognizes world-class researchers selected for their exceptional research performance, demonstrated by production of multiple highly cited papers that rank in the top 1% by citations for field and year in Web of Science.